NKNilgün Kansak

Nilgün Kansak

*This is an algorithmically generated author record based on publicly available information.

Nilgün Kansak has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    KARBAPENEM DİRENÇLİ KLEBSIELLA PNEUMONIAE İZOLATLARINDA SEFTAZİDİM-AVİBAKTAM VE KOLİSTİN DİRENCİNİN YILLAR İÇİNDE DEĞİŞİMİNİN İZLENMESİ

    by Gülsüm Kaya, Neslihan Arıcı, Nilgün Kansak, Rıza Adaleti, Sebahat Aksaray

    Karbapenem dirençli Klebsiella pneumoniae (KDKP) enfeksiyonları, sağlık kurumlarında yüksek morbidite ve mortaliteye yol açan önemli bir problemdir. Özellikle tedavide son seçenek olarak kullanılan seftazidim-avibaktam (CZA) ve kolistine karşı direnç oranları giderek artmaktadır. Bu çalışmanın amacı, hastanemiz yoğun bakım üniteleri ve servislerinde izole edilen KDKP suşlarında CZA ve kolistin direncinin yıllara göre değişimini değerlendirmektir. Çalışmaya Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıbbi Mikrobiyoloji Laboratuvarı’nda, Ocak 2022-Haziran 2025 tarihleri arasında çeşitli klinik örneklerden etken olarak izole edilen KDKP izolatları dahil edildi. İzolatların tanımlaması MALDI-TOF MS ile, CZA duyarlılığı disk difüzyon yöntemiyle, kolistin duyarlılığı ise sıvı mikrodilüsyon temelli ticari bir test ile belirlenmiştir. Antibiyotik duyarlılık sonuçları EUCAST kriterlerine göre değerlendirilmiştir. Toplam 643 KDKP izolatının %60.2’si yoğun bakım ünitesinden, %21.4’ü cerrahi ve %18.4’ü dahili servislerden gönderilmiştir. KDKP’nin etken olduğu enfeksiyonlar en sık kan (%29.1), idrar (%25.0) ve trakeal aspirat (%24.0) örneklerinden izole edilmiştir. Kolistin direnç oranının %38.2 olduğu ve yıllar içinde direnç oranlarındaki artışın (%38.9, %33.1, %36.7 ve %42.6) istatistiksel olarak anlamlı olmadığı görüldü (p=0.394). CZA direncinin ise %42.6 olduğu ve yıllara göre sırasıyla; %18.2, %31.4, %48.5 ve %52.7 olarak değiştiği ve bu artışın istatistiksel olarak anlamlı derecede yüksek olduğu saptandı (p


  • Open Access

    YOĞUN BAKIM KLİNİĞİMİZDE YATAN HASTALARIN KAN KÜLTÜRLERİNDE EN SIK ÜREYEN GRAM NEGATİF ÇOMAKLARIN DUYARLILIK TEST SONUÇLARININ DEĞERLENDİRİLMESİ: SEKİZ YILLIK VERİ

    by Rıza Adaleti, Neslihan Arıcı, Nilgün Kansak, Recep Balık, Sebahat Aksaray

    Gram negatif bakterilerin neden olduğu kan dolaşımı enfeksiyonları, yoğun bakım ünitelerinde önemli morbidite ve mortalite nedenleridir. Bu çalışmada, 2016 ve 2023 yılları arasında yoğun bakım servisinde yatan hastaların kan kültürlerinden izole edilen, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa ve Acinetobacter baumannii bakterilerinin antibiyotiklere karşı duyarlılıkları araştırılmış ve duyarlılık oranlarında anlamlı değişim olup olmadığı irdelenmiştir. E. coli (n= 811) için en düşük duyarlılık oranları ampisilin, amoksisilin/klavulanat (AMC) ve seftazidim; en yüksek duyarlılık oranları karbapenem grubu antibiyotikler için saptanmıştır. Bu bakteride, sekiz senelik dönemde piperasilin/tazobaktam (TZP), gentamisin ve siprofloksasin için duyarlılık oranları anlamlı düzeyde farklı bulunmuştur (p≤0.05). K. pneumoniae’da (n= 612) en düşük duyarlılık oranı AMC, en yüksek duyarlılık oranları aminoglikozidlere karşı saptanmıştır. Bu izolatlarda duyarlılık oranlarında anlamlı bir fark saptanmamıştır (p>0.05). A. baumannii’de (n= 327) en düşük duyarlılık oranları karbapenem ve florokinolonlar için, en yüksek duyarlılık oranları aminoglikozidlere karşı saptanmıştır. Bu bakteride aminoglikozidlere karşı duyarlılık oranlarında anlamlı düzeyde fark saptanmıştır (p≤0.05). P. aeruginosa (n= 270) kökenlerinde, en düşük duyarlılık oranları TZP, en yüksek duyarlılık oranları amikasine karşı saptanmıştır. Bu izolatlarda, duyarlılık oranlarında anlamlı fark saptanmamıştır (p>0.05). Değerlendirilen bakterilerde antibiyotiklere karşı duyarlılık oranları yıllar içinde dalgalı seyir izlense de genelde azalma eğilimi gözlenmiştir.

  • Open Access

    Evaluation of syphilis co-infection and monitoring of rapid plasma reagin (RRP) titer according to syphilis-stage in human immunodeficiency virus-infected patients

    by Neslihan Arici, Handan Ankarali, Nilgün Kansak, Rıza Adaleti̇, Sebahat Aksaray

    Aim: Syphilis co-infection in HIV-infected patients is associated by a delayed serological response. The aim of this study is to obtain current data on the frequency of HIV/syphilis co-infection, the monitoring of rapid plasma reagin (RPR) titer after treatment, and factors affecting the serologic response. Methods: Serological tests for syphilis of HIV patients followed between January 2015 and March 2023 were evaluated retrospectively. Demografic data (age, sex), level of HIV RNA, RPR, Treponema pallidum haemagglutination test (TPHA), and syphilis stage were obtained from hospital electronic database. Serological response was defined according to Centers for Disease Control and Prevention (CDC) criteria. Results: Syphilis co-infection was detected in 36.2% of the patients, all of them were male. Distribution of syphilis stage was primary 2.9%, secondary 9.7%, latent 80.6%, and neurosyphilis 6.8%, respectively. All patients with primary, secondary, and neurosyphilis had ≥4-fold decrease in RPR titer within 12 months after treatment, while two patients with latent syphilis didn’t have a decrease in titer within 12-24 months. Overall serologic response was 95.8%. Comparing the time to a 4-fold decrease in the RPR titer in terms of syphilis stage, there was no statistically significant difference. Patients with initial RPR titer >1: 32 achieved faster serologic response than those with initial RPR titer ≤1: 32. Conclusion: HIV/syphilis coinfection rate was notably high. It is promising that most patients had a serologic response within the time-frame defined by the CDC. It should be considered that treatment response may take longer in patients with an initial RPR titer ≤32. Further prospective studies are needed to understand the factors associated with serologic response in HIV/syphilis co-infected patients.

  • Open Access

    In Vitro Efficacy of Ceftazidime-Avibactam in Carbapenem Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa Isolates as Causative Agents of Ventilator-Associated Pneumonia

    by Neslihan Arici, Nilgün Kansak, Rıza Adaleti̇, Sümeyye İlhan, Rümeysa Özdemi̇r, Seniha Şenbayrak, Sebahat Aksaray

    Ventilatör ilişkili pnömoni (VİP), yoğun bakım ünitesi (YBÜ) kaynaklı en ciddi enfeksiyonlardan biridir. Bu çalışmanın amacı, hastanemizde VİP etkeni olarak izole edilmiş karbapenem dirençli Klebsiella pneumoniae ve Pseudomonas aeruginosa izolatlarına karşı seftazidim-avibaktamın in vitro etkinliğini saptamaktır. Endotrakeal aspirat (ETA) tarama örneklerinde etken mikroorganizma ile kolonizasyon sıklığı, VİP ile ilişkili risk faktörleri ve hasta sağ kalım sonuçlarının belirlenmesi de amaçlanmıştır. Bu retrospektif çalışmaya, Eylül 2021- Aralık 2022 tarihleri arasında Haydarpaşa Numune Hastanesi YBÜ’nde yatan ve 48 saatten daha fazla mekanik ventilasyon desteği görmüş ve VİP tanısı almış hastalar ve ETA örnekleri dahil edildi. Suşların identifikasyonunda MALDI-TOF (VITEK-MS, bioMérieux, Fransa), antibiyotik duyarlılığının belirlenmesinde VITEK 2 otomatize sistemi (bioMérieux, Fransa) kullanıldı. Seftazidim-avibaktam duyarlılığı disk difüzyon yöntemi ile belirlenerek, dirençli bulunan suşlar ayrıca gradiyent difüzyon yöntemi (MIC strip, Liofilchem, İtalya) ile çalışıldı. Suşların antibiyotik duyarlılığı, European Committee on Antimicrobial Susceptibility Testing (EUCAST) kriterlerine göre değerlendirildi. Hastalara ait mikrobiyolojik veriler laboratuvar iletişim sistemi üzerinden, klinik bilgiler ise hastane iletişim sisteminde yer alan elektronik tıbbi kayıtlardan elde edildi. Çalışmaya VIP gelişen ve örneklerinden karbapenem dirençli K. pneumoniae (n=18) ve P. aeruginosa (n=22) izole edilen 40 hasta dahil edildi. K. pneumoniae izolatlarının %22.2’si, P. aeruginosa izolatlarının ise %86.4’ü seftazidim-avibaktama dirençli bulundu. K. pneumoniae üremesi olan hastaların %16.6’sında, P. aeruginosa üremesi olanların %31.8’inde sürveyans ETA örneklerinde aynı etkenlerle kolonizasyon varlığı saptandı. VİP öncesi, en sık kullanılan antibiyotiklerin meropenem ve piperasilin-tazobaktam olduğu görüldü. K. pneumoniae üremesi olan hastalarda mortalite %83.4 iken, P. aeruginosa üremesi olanlarda %95.5 idi. Çalışmamızda karbapenem dirençli P.aeruginosa izolatlarında belirlenen yüksek direnç oranının da işaret ettiği gibi, son seçenek antibiyotiklerden biri olan seftazidim- avibaktamın, ciddi enfeksiyonlarda zamanında ve etkin kullanımı için, düzenli direnç takibininin yapılması gereklidir. Ayrıca kolonizasyonu saptamada sürveyans ETA kültürlerinin alınması, olası VİP etkeni mikroorganizmaların önceden bilinmesi için önemlidir.


  • Carbapenem-resistant Klebsiella pneumoniae outbreak with monoclonal spread: Evaluation of resistance genes and ceftazidime-avibactam susceptibility

    by Neslihan Arıcı, Elif Seren Tanrıverdi, Şeyma Çalık, Nilgün Kansak, Rıza Adaleti, Barış Otlu, Sebahat Aksaray


  • Evaluation of In vitro Efficacy of Meropenem/Colistin and Meropenem/Fosfomycin Combinations on Multidrug Resistant Gram-Negative Bacilli

    by Rıza Adaleti, Yaşar Nakipoğlu, Neslihan Arıcı, Nilgün Kansak, Şeyma Çalık, Seniha Şenbayrak, Recep Balık, Sebahat Aksaray

    The rate of extensively drug-resistant and pan-resistant gram-negative rods isolated as infectious agents is increasing around the world and in Turkiye. One of the important options in the treatment of these infections is the combined use of antibiotics. Therefore, the aim of this study was to investigate the in vitro effect of meropenem/colistin and meropenem/fosfomycin combinations on carbapenem-resistant gram-negative bacilli isolated as infectious agents. Escherichia coli (n= 6), Klebsiella pneumoniae (n= 10), Pseudomonas aeruginosa (n= 5), and Acinetobacter baumannii (n= 6) isolates were recovered from blood and tracheal aspirate samples of patients hospitalized in our hospital's intensive care unit were included in the study. In the first stage of the combination study, minimal inhibitory concentrations (MIC) were investigated by broth microdilution for meropenem and colistin, and agar dilution methods for fosfomycin. In the second stage of the study, synergy, partial synergy, indifference, and antagonistic effects were investigated with the checkerboard method for the meropenem/colistin combination and the agar dilution method for the meropenem/fosfomycin combination. The checkerboard results were interpreted as follows: fractional inhibitory concentration index (FICI) values <= 0.5 synergy, < 0.5-<= 1 partial synergy, > 1-<= 4 indifference and FIC values of > 4 antagonism. MIC values obtained in the study were interpreted according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. Of the 27 isolates studied with the broth microdilution method, 63% were found to be colistin-resistant and 37% susceptible. The MIC values of fosfomycin against Enterobacterales group bacteria were found to be in the range of 2-2048 mg/L. Two of the six E.coli isolates and nine of the 10 K.pneumoniae isolates were found to be resistant to fosfomycin (IV). The MIC values of >= 128 mg/L were found in all 11 non-fermentative gram-negative rods with intrinsic resistance to fosfomycin. In the combination of meropenem/colistin, synergy and partial synergy were observed in 11 (40.7%) of 27 isolates, an indifference effect was observed in 13 (48.2%), and antagonistic effects were observed in three (11.1%) of the isolates. The synergy and partial synergy effects of this combination were 37.5% for Enterobacterales group bacteria, 50% for E.coli, and 30% for K.pneumoniae. Regarding the 11 non-fermentative gram-negative rods included in the study, 83.3% synergy and partial synergy was found in A.baumannii for the meropenem/colistin combination, while no synergy and partial synergistic effect was found in P.aeruginosa. Meropenem/fosfomycin synergy and partial synergy effects were 83.3% (5/6) for E.coli, 100% (8/8) for K.pneumoniae, 100% (6/6) for A.baumannii, and 25% (1/4) for P.aeruginosa. In all of the isolates studied, meropenem/fosfomycin combination was found to be more effective than the meropenem/colistin combination. It would be meaningful to support these data obtained in vitro with clinical efficacy results to be obtained as a result of the application of antibiotics in vivo, taking into account the pharmacokinetic and pharmacodynamic properties of the antibiotics used in this study.


  • A Case of Mycobacterium abscessus Identified by Suspicious Gram Staining in the Blood Culture of a Patient with Chronic Renal Failure

    by Rıza Adaleti, Nilgün Kansak, Neslihan Arıcı, Ahmet Balıkçı, Yasemin Uzunöner, Sebahat Aksaray

    Mycobacterium abscessus (M.abscessus), which is from the group of non-tuberculosis mycobacteria and is widely found in the natural environment, has been reported with increasing frequency as the causative agent of various infections; especially in the lower respiratory tract and in immuncompromised people. In this report, a case of M.abscessus, which developed tubular adenoma, pancytopenia and sepsis on the basis of chronic renal failure (CRF) was diagnosed by suspecting the causative agent in the Gram stain examination prepared from blood culture, was presented. A 49-year-old patient with CRF, who had complaints of weight loss, weakness, and loss of appetite for the last six months, admitted to the emergency department with a 7-8-day history of severe diarrhea and fever. Besides other tests, as the white blood cell count was 1.6 x 103/mu l, neutrophil count was 80.6%, hemoglobin was 9.3 g/ dl and the platelet value was 36 x 103/mu l in the blood samples, the patient was first taken into internal medicine service and then to the intensive care unit with a preliminary diagnosis of hypotension and sepsis. Meropenem and teicoplanin were started with the preliminary diagnosis of peritonitis in the internal medicine service. In addition to other tests, on the fifth day of antibiotic treatment, two consecutive sets of blood cultures were taken and sent to the microbiology laboratory. A positive signal was obtained from two aerobic blood culture samples at 42 and 45 hours of incubation in the BacT/Alert device. No bacteria were observed in the Gram staining of these samples and Erhlich Ziehl Neelsen (EZN) staining was performed because the structures considered as dye residues were noted as a result of the examination. Acid-fast bacteria were observed in the EZN-stained slide examination, and a panic report was given to the clinician. The patient died shortly after the notification was made in the evening hours. On culture plates inoculated after a positive signal, at the end of two days of aerobic incubation at 37 degrees C, small smooth S colonies grew on chocolate and sheep blood agar. Growing bacteria were detected as positive by EZN staining and identified as M.abscessus with 99.9% confidence by MALDI-TOF MS. After the bacterium was named as M.abscessus, the isolates were sent to the tuberculosis central laboratory of Sureyyapaa Chest Diseases and Thoracic Surgery Hospital for molecular typing. After DNA extraction from the growing colonies and polymerase chain reaction (PCR), they were typed using the GenoType NTM-DR (Hain Lifescience GmbH, Germany) kit and identified as M.abscessus, consistent with the MALDITOF MS result. After the species level identification, the erm, rrl (clarithromycin, azithromycin), and rrs (kanamycin, amikacin, and gentamicin) genes were investigated in the isolate, and it was determined that the bacteria were resistant to macrolides and sensitive to aminoglycosides. In the clinic, it should be noted that, non-tuberculous mycobacteria may play a role as an agent in immunocompromised people. On the other hand, it should be considered that non-tuberculosis bacteria may be the causative agent, with gram-positive bacilli appearing as stain residues or pale staining in Gram stains made from samples of such patients. As in this case, if the agent is seen as dye residue in blood culture Gram staining samples, it may be life-saving to suspect the agent and to report the result to the clinician accurately and quickly after EZN staining.


  • Open Access

    Can colistin susceptibility results determined in multidrug resistant Gram-negative bacteria be used for polymyxin B?

    by Rıza Adaleti, Nilgün Kansak, Şeyma Çalık, Neslihan Arıcı, Seniha Şenbayrak, Sebahat Aksaray

    Introduction: The present study aimed to compare the MIC values of colistin and polymyxin B in fermentative and non-fermentative Gram-negative bacteria and to examine whether the susceptibility results determined with colistin can be used for polymyxin B. Materials and Methods: A total of 268 strains of Escherichia coli ( E. coli ), Klebsiella pneumoniae ( K. pneumoniae ), Pseudomonas aeruginosa ( P. aeruginosa ), and Acinetobacter baumannii ( A. baumannii ) isolates were included in the study. The reference broth microdilution and the results were evaluated according to CLSI recommendations. Results: Of the 268 strains, 40.7% were found to be colistin resistant and 34% polymyxin B resistant. Essential agreement (EA) and categorical agreement (CA) ratios for all isolates were found to be 81.3% and 85.1%, respectively. Identical MIC values were found for colistin and polymyxin B in 104 isolates (38.8%), and this rate was 31.1% and 48.7% in Enterobacterales and non-fermentative bacteria, respectively. Colistin resistance rates were 25.4% for E. coli , 67.4% for K. pneumoniae , 23.8% for P. aeruginosa , and 31.5% for A. baumannii . Polymyxin B resistance rates were 18.6% for E. coli , 64.1% for K. pneumoniae , 19% for P. aeruginosa , and 16.7% for A. baumannii . Conclusion: According to the results of the study, it was concluded that the MIC values of colistin and polymyxin B antibiotics in all bacteria were not compatible with each other. Colistin susceptibility results cannot be used for treatment with polymyxin B, despite CLSI's recommendation.